[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiang Wei\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100464822","transapical-beating-heart-septal-myectomy-in-patient-with-hypertrophic-obstructive-cardiomyopathy-100464822",false,"NCT05332691","Transapical Beating-heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy","Minimally Invasive Transapical Septal Myectomy in the Beating Hearts for the Treatment of Hypertrophic Obstructive Cardiomyopathy: Safety and Efficacy Results of a Phase I First-in-man Clinical Trial","Inclusion Criteria:\n\n1. Patients whose resting or provoked left ventricular outflow tract gradient \\> 50 mmHg, and maximal ventricular septal wall thickness ≥ 15 mm.\n2. Patients with heart function of New York Heart Association ≥ class II.\n3. Patients with drug-refractory symptoms or intolerable to pharmaceutical therapies.\n4. Patients who was informed the nature of the clinical trial, consented to participate in all of the activities of the clinical trial, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients who were pregnant.\n2. Patients who had concomitant diseases such as intrinsic valvular disease or coronary artery disease that needed open-heart surgery.\n3. Patients who had severe heart failure with left ventricle ejection fraction \\\u003C 40%.\n4. Patients whose estimated life expectancy \\\u003C 12 m.\n5. Patient who were non-compliant.\n6. Patients under circumstances which were considered not suitable or prohibitive for participating the clinical trial at the discretion of the attending medical team and the researchers.","ALL","8 Years",{"count":19,"type":20},1000,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy. This is a prospective, single-arm, single-center, first-in-man study.",[26],"Hypertrophic Obstructive Cardiomyopathy",[26,28,29,30,31,32,33,34],"Septal Myectomy","Systolic Anterior Motion","Left Ventricle Outflow Tract Obstruction","Mitral Regurgitation","Transapical","Off-pump","Minimally invasive","RECRUITING","2024-11-05",{"date":38,"type":39},"2024-11-07","ACTUAL",{"date":41,"type":39},"2022-04-15",{"date":43,"type":20},"2025-12-30",{"name":45,"class":46},"Xiang Wei","OTHER",""]